Orthofix Medical 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Massimo Calafiore

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.08%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	1.6yrs

최근 관리 업데이트

Recent updates

CEO

Massimo Calafiore (52 yo)

less than a year

테뉴어

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Geoffrey Gillespie	VP & Corporate Controller	3.7yrs	US$887.05k	0.0088% € 59.3k
Massimo Calafiore	President	less than a year	데이터 없음	0.079% € 530.9k
Julie Andrews	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Aviva McPherron	President of Global Operations & Quality	less than a year	데이터 없음	데이터 없음
Julie Dewey	Chief Investor Relations & Communications Officer	less than a year	데이터 없음	데이터 없음
Jill Mason	Chief Compliance & Risk Officer	no data	데이터 없음	데이터 없음
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	데이터 없음	데이터 없음
Stephanie Walsh	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Ehab Esmail	Senior Vice President of Global Quality	6yrs	데이터 없음	데이터 없음
Tyler Lipschultz	President of Global Biologics	2yrs	데이터 없음	데이터 없음
Beau Standish	President of Global Enabling Technologies	no data	데이터 없음	데이터 없음
Lucas Vitale	Chief People & Business Operations Officer	less than a year	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: OM2 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Massimo Calafiore	President	less than a year	데이터 없음	0.079% € 530.9k
John Henneman	Independent Director	2yrs	US$355.42k	0.090% € 607.0k
Alan Bazaar	Independent Director	1.1yrs	US$300.00k	0% € 0
Jason Hannon	Independent Director	4.6yrs	US$376.25k	0.012% € 80.7k
Charles Kummeth	Independent Director	1.1yrs	US$300.00k	0.039% € 264.6k
Michael Finegan	Independent Chair of the Board	1.1yrs	US$300.00k	0% € 0
Michael Paolucci	Independent Director	8.8yrs	US$376.25k	0.032% € 212.8k
Shweta Maniar	Independent Director	2yrs	US$355.42k	0.015% € 101.0k
Wayne Burris	Independent Director	1.6yrs	US$539.70k	0.017% € 112.6k

1.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: OM2 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/20 19:11
장 마감 주가	2025/01/17 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Orthofix Medical Inc. 19 애널리스트 중 5 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Gregory Chodaczek	Boenning & Scattergood, Inc.
Michael Gorman	BTIG
William Plovanic	Canaccord Genuity

Orthofix Medical 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Recent updates

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$0.78 loss in 3Q 2023)

Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024

Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law

Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024

Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Orthofix Medical Inc. and Seaspine Holdings Corporation

No longer forecast to breakeven

Scott+Scott Attorneys At Law LLP Files Securities Class Action Lawsuit in the United States District Court for the Eastern District of Texas Against Orthofix Medical, Inc

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.88 loss per share (vs US$1.07 loss in 2Q 2023)

Orthofix Medical Inc. Revises Revenue Guidance for the Full Year 2024

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. to Report Q2, 2024 Results on Aug 06, 2024

Orthofix Medical Inc. Announces First Implant of Fitbone Transport and Lengthening System

Orthofix Medical Inc.(NasdaqGS:OFIX) dropped from Russell 2000 Value-Defensive Index

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail

Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.71 loss in 1Q 2023)

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

New minor risk - Profitability

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Full year 2023 earnings released: US$4.12 loss per share (vs US$0.98 loss in FY 2022)

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.53 loss in 3Q 2022)

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought €95k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Second quarter 2023 earnings released: US$1.07 loss per share (vs US$0.12 profit in 2Q 2022)

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold €146k worth of stock

First quarter 2023 earnings released: US$1.71 loss per share (vs US$0.22 loss in 1Q 2022)

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Full year 2022 earnings released: US$0.98 loss per share (vs US$1.95 loss in FY 2021)

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CFO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

High number of new directors

Third quarter 2022 earnings released

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.